917877-73-7 Usage
Description
cis-4-[1-(Cyclohexyl)-2-(2-piperidinyl)ethyl]cyclohexanol is a complex organic compound with a unique molecular structure. It is characterized by a cyclohexane ring with a 4-cis configuration, which is substituted by a 1-cyclohexyl-2-(2-piperidinyl)ethyl group. cis-4-[1-(Cyclohexyl)-2-(2-piperidinyl)ethyl]cyclohexanol is an off-white to pale yellow solid, indicating its potential stability and insolubility in water.
Uses
As a metabolite of Perhexiline:
cis-4-[1-(Cyclohexyl)-2-(2-piperidinyl)ethyl]cyclohexanol is used as a metabolite in the pharmaceutical industry for Perhexiline. It plays a crucial role in the metabolism and pharmacokinetics of the drug, contributing to its therapeutic effects and safety profile.
In Drug Development:
cis-4-[1-(Cyclohexyl)-2-(2-piperidinyl)ethyl]cyclohexanol can be used as a starting material or intermediate in the synthesis of new pharmaceutical compounds. Its unique structure and properties make it a promising candidate for the development of novel drugs with potential therapeutic applications.
In Chemical Research:
Due to its complex structure and unique properties, cis-4-[1-(Cyclohexyl)-2-(2-piperidinyl)ethyl]cyclohexanol can be used as a subject of study in chemical research. It can provide insights into the synthesis, reactivity, and potential applications of similar compounds, contributing to the advancement of organic chemistry and related fields.
In Material Science:
The off-white to pale yellow solid nature of cis-4-[1-(Cyclohexyl)-2-(2-piperidinyl)ethyl]cyclohexanol suggests that it may have potential applications in material science. Its stability and insolubility in water could make it suitable for use in the development of new materials with specific properties, such as coatings, adhesives, or polymers.
In Analytical Chemistry:
The unique structure and properties of cis-4-[1-(Cyclohexyl)-2-(2-piperidinyl)ethyl]cyclohexanol can also be utilized in analytical chemistry. It can serve as a reference compound or standard for the development and validation of analytical methods, such as chromatography, mass spectrometry, or spectroscopy.
Check Digit Verification of cas no
The CAS Registry Mumber 917877-73-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,1,7,8,7 and 7 respectively; the second part has 2 digits, 7 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 917877-73:
(8*9)+(7*1)+(6*7)+(5*8)+(4*7)+(3*7)+(2*7)+(1*3)=227
227 % 10 = 7
So 917877-73-7 is a valid CAS Registry Number.
InChI:InChI=1/C19H35NO/c21-18-11-9-16(10-12-18)19(15-6-2-1-3-7-15)14-17-8-4-5-13-20-17/h15-21H,1-14H2/t16-,17?,18+,19?
917877-73-7Relevant articles and documents
Development of Fluorinated Analogues of Perhexiline with Improved Pharmacokinetic Properties and Retained Efficacy
Tseng, Chih-Chung,Noordali, Hannah,Sani, Monica,Madhani, Melanie,Grant, Denis M.,Frenneaux, Michael P.,Zanda, Matteo,Greig, Iain R.
, p. 2780 - 2789 (2017/04/21)
We designed and synthesized perhexiline analogues that have the same therapeutic profile as the parent cardiovascular drug but lacking its metabolic liability associated with CYP2D6 metabolism. Cycloalkyl perhexiline analogues 6a-j were found to be unsuitable for further development, as they retained a pharmacokinetic profile very similar to that shown by the parent compound. Multistep synthesis of perhexiline analogues incorporating fluorine atoms onto the cyclohexyl ring(s) provided a range of different fluoroperhexiline analogues. Of these, analogues 50 (4,4-gem-difluoro) and 62 (4,4,4′,4′-tetrafluoro) were highly stable and showed greatly reduced susceptibility to CYP2D6-mediated metabolism. In vitro efficacy studies demonstrated that a number of derivatives retained acceptable potency against CPT-1. Having the best balance of properties, 50 was selected for further evaluation. Like perhexiline, it was shown to be selectively concentrated in the myocardium and, using the Langendorff model, to be effective in improving both cardiac contractility and relaxation when challenged with high fat buffer.
